Cerebral venous thrombosis in a patient with Crohn's disease.
- Author:
Young Hak CHO
1
;
Min Kyu CHAE
;
Jae Myung CHA
;
Joung Il LEE
;
Kwang Ro JOO
;
Hyun Phil SHIN
;
Il Hyun BAEK
;
Jung Won JEON
;
Jun Uk LIM
;
In Taik HONG
;
Hye Jin KI
;
Jae Bin KANG
Author Information
- Publication Type:Case Report
- Keywords: Inflammatory bowel diseases; Crohn disease; Cerebral venous thrombosis; Complication; Anticoagulation
- MeSH: Adolescent; Brain; Crohn Disease*; Female; Follow-Up Studies; Headache; Heparin; Humans; Inflammatory Bowel Diseases; Jugular Veins; Leg; Magnetic Resonance Imaging; Mesenteric Veins; Phlebography; Rivaroxaban; Superior Sagittal Sinus; Thrombosis; Veins; Venous Thromboembolism; Venous Thrombosis*; Vomiting
- From:Intestinal Research 2016;14(1):96-101
- CountryRepublic of Korea
- Language:English
- Abstract: Patients with inflammatory bowel disease (IBD) have an elevated risk of venous thromboembolism compared with the general population. The most common sites of venous thromboembolism in IBD patients are the deep veins of the legs, the pulmonary system, and portal and mesenteric veins. However, cerebral venous thrombosis is rarely associated with IBD. This report describes a case of cerebral venous thrombosis in a patient with Crohn's disease. A 17-year-old girl, diagnosed 4 years earlier with Crohn's disease, presented with headache and vomiting. Magnetic resonance imaging of the brain with venography showed venous thrombosis in the cortical veins, superior sagittal sinus, right transverse sinus, and right internal jugular vein. The patient immediately started anticoagulation therapy with intravenous heparin infusion followed by daily oral rivaroxaban 10 mg. Follow-up imaging after 2 weeks showed resolution of the thrombosis, with recanalization of the cortical veins, superior sagittal sinus, right transverse sinus, and right internal jugular vein. She continued rivaroxaban therapy for 6 months, and remained well, without neurologic sequelae. A high level of concern for cerebral venous thrombosis may be important when treating active IBD patients, because anticoagulation treatment can prevent fatal complications.
